Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPOSE trial of lutetium (177Lu) edotreotide versus best standard of care in aggressive well-differentiated GEP-NETs
NL-OMON56413Phase 3Recruiting
- Sponsor
- ITM Isotope Technologies Munich
- Start
- Mar 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor comparing PRRT with lutetium (177Lu) edotreotide with Best standard of care (2 arms). Primary endpoint: Progression-free survival. Started Mar 2022; status: recruiting.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON56413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56413.